Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.
For extended treatment of symptomatic VTE in adults with cancer and CrCl below 30 mL/min, use anti-Xa monitoring to determine dose. Target 0.5-1.5 units/mL at 4-6 hours after dosing after 3-4 doses.
Limits and monitoring
This target is specific to the stated population and indication. Verify bleeding risk and neuraxial procedure timing separately.
For adults at CrCl below 30 mL/min, including HD or CAPD, give the indication-specific dose every 48 hours: 4 mg/kg for complicated skin infection or 6 mg/kg for S. aureus bacteremia. Dose after HD when feasible.
Limits and monitoring
At CrCl at least 30 the usual interval is 24 hours. Monitor renal function and CPK more frequently in renal impairment.
Renal impairment categories as defined by the cited product label
Renal action or finding
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis.
Limits and monitoring
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Renal impairment categories as defined by the cited product label
Renal action or finding
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis.
Limits and monitoring
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Severe renal dysfunction and dialysis increase the risk of denosumab-associated hypocalcemia. Monitor calcium and assess calcium and vitamin D intake, especially at CrCl below 30 mL/min or during dialysis.
Limits and monitoring
Verify the oncology Xgeva product and indication. Comparable exposure does not eliminate the risk of hypocalcemia.
